The Effects of Trimetazidine on P-Wave Duration and Dispersion in Heart Failure Patients

---

GUNES Y., Tuncer M., GUNTEKIN U., Akdag S., GÜMRÜKÇÜOĞLU H. A.

PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, vol.32, no.2, pp.239-244, 2009 (SCI-Expanded, Scopus)

• Publication Type: Article / Article
• Volume: 32 Issue: 2
• Publication Date: 2009
• Doi Number: 10.1111/j.1540-8159.2008.02208.x
• Journal Name: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.239-244
• Van Yüzüncü Yıl University Affiliated: Yes

Abstract

Background: P-wave duration and dispersion (PWD) have been shown to be noninvasive predictors for development of atrial fibrillation. Thus, it may be possible to attenuate atrial fibrillation risk through normalization of P-wave duration and dispersion. Trimetazidine, a metabolic modulator, has been reported to improve cardiac function in heart failure (HF) patients.